Clinical Trial

A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

Completed Phase 3
View on ClinicalTrials.gov →
Summary
To compare the efficacy and safety of HR17031 injection and insulin glargine, including the changes of efficacy indicators such as HbA1c, fasting blood glucose, body weight and safety indicators such as adverse events and hypoglycemic events.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-06.
Status change: Active, Not Recruiting → Completed 2026-01-12
Trial Details
NCT Number NCT06871761
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Adult Patients With Type 2 Diabetes
Enrollment 393 participants
Start Date 2024-05-08
Primary Completion 2025-05-13 (estimated)
Study Completion 2025-05-13 (estimated)
Updated on ClinicalTrials.gov 2026-01-13